

## Référence bibliographiques:

1. Ben Redjeb S, Boutiba-Ben Boubaker I. L'antibio-résistance en Tunisie – LART- Données 1999-2003. LAB-MDT-03- Tunis. Edition Décembre 2005.
2. Armed project. Antibiotic resistance surveillance and control in the mediterranean region. <http://www.rivm.nl/earss/armed/>
3. Borg MA, Scicluna E, de Kraker M, van de Sande-Bruinsma N, Tiemersma E, Gür D, Ben Redjeb S, Rasslan O, Elnassar Z, Benbachir M, Pieridou Bagatzouni D, Rahal K, Daoud Z, Grundmann H, Monen J. Antibiotic resistance in the southeastern Mediterranean--preliminary results from the ARMed project. Euro Surveill. 2006;11(7):164-7.
4. Borg MA, Van De Sande-Bruinsma N, Scicluna E, Kraker M et al. Antimicrobial resistance in invasive strains of *Escherichia coli* from southern and eastern Mediterranean laboratories. Clin Microbiol Infect. 2008;(14):789-96.
5. Falagas ME, Rafailidis PI. When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. Shock. 2007;27(6):605-9.
6. Bruyère F, Cariou G, Boiteux J-P, Hoznek A, J.-P. Mignard, Escaravage L, Bernard L, Sotto A, Soussy C-J and Coloby P. Pyélonéphrites aiguës. Prog Urol.2008;18(1):14-8.
7. Shigemura K, Arakawa S, Miura T, Nakano Y , Tanaka K and Fujisawa M. Significance of fluoroquinolone resistant *Escherichia coli* in urinary tract infections. Jpn J Infect Dis.2008;61:226-8.
8. The European Antimicrobial Resistance Surveillance System. [www.rivm.nl/earss/database/](http://www.rivm.nl/earss/database/)
9. Killgore KM. Risk Factors for Community-Acquired Ciprofloxacin-Resistant *Escherichia coli* Urinary Tract Infection. Ann Pharmacother. 2004;38(7):1148-52.
10. Huotari K, Tarkka E, Valtonen V, Kolho E. Incidence and Risk Factors for Nosocomial Infections Caused by Fluoroquinolone-Resistant *Escherichia coli*. Eur J Clin Microbiol Infect Dis.2003;22:492–5.
11. Boyd LB, Atmar RL, Randall GL, Hamill RJ, Steffen D and Zechiedrich L. Increased fluoroquinolone resistance with time in *Escherichia coli* from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infectious Diseases. 2008;8(4) : 1-7.
12. Ktari S, Arlet G, Mnif B, Gautier V, Mahjoubi F, Ben Jemaa M, Bouaziz M and Hammami A. Emergence of Multidrug-Resistant *Klebsiella pneumoniae* Isolates Producing VIM-4 Metallo- $\beta$ -Lactamase, CTX-M-15 Extended-Spectrum  $\beta$ -Lactamase, and CMY-4 AmpC  $\beta$ -Lactamase in a Tunisian University Hospital. Antimicrob Agents Chemother. 2006; 50(12): 4198–4201.
13. Jarlier V. Bactéries multirésistantes dans les hôpitaux français : des premiers indicateurs au Réseau d'alerte d'investigation et de surveillance des infections nosocomiales (Raisin). Bull Epid Heb 2004;32-33:148-51.

14. Lepelletier D, Perron S, Huguenin H, Picard M, Bemer P, Caillon J, Juvin ME and Drugeon H. Quelles stratégies découlent de la surveillance des bactéries multirésistantes aux antibiotiques afin de mieux maîtriser leur diffusion? *Path Biol.*2003;51(8-9):464-8.
15. Borg MA, Cookson BD, Scicluna E; ARMed Project Steering Group and Collaborators. Survey of infection control infrastructure in selected southern and eastern Mediterranean hospitals. *Clin Microbio Infect.* 2007;13(3):344-6.
16. Enquête de prévalence nationale 2001.  
[http://www.invs.sante.fr/publications/2003/raisin\\_ennp\\_2001/index.html](http://www.invs.sante.fr/publications/2003/raisin_ennp_2001/index.html)
17. Institut de veille sanitaire. Enquête nationale de prévalence des infections nosocomiales, juin 2006. Résultats préliminaires, janvier 2007.  
[http://www.invs.sante.fr/publications/2007/ennp2006\\_resultats\\_preliminaires/index.html](http://www.invs.sante.fr/publications/2007/ennp2006_resultats_preliminaires/index.html)
18. Philippon A, Ben Redjeb S, Fournier S, Ben Hassen A. Epidemiology of extended spectrum beta-lactamases. *Infection.*1989;17(5):347-54.
19. Mamlouk K, Boutiba-Ben Boubaker I, Gautier V, Vimont S, Picard B, Ben Redjeb S, Arlet G. Emergence and outbreaks of CTX-M beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* strains in a Tunisian hospital. *J Clin Microbiol.* 2006;44(11):4049-56.
20. Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B, Ben Redjeb S, Bercion R, Gautier V, Arlet G. Clonal dissemination of a CTX-M-15 beta-lactamase-producing *Escherichia coli* strain in the Paris area, Tunis, and Bangui. *Antimicrob Agents Chemother.* 2006;50(7):2433-8.
21. Canton R and Coque TM. The CTX-M beta-lactamase pandemic. *Curr Opin Microbiol.*2006;9(5):466-75.
22. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, Leavitt A and Carmeli Y. Influx of extended spectrum beta-lactamase producing *Enterobacteriaceae* into the hospital. *Clin Infect Dis.*2006 ;42(7):925-34.
23. Lartigue MF, Poirel L, Decousser JW and Nordmann P. Multidrug resistant *Shigella sonnei* and *Salmonella enterica* serotype Typhimurium isolates producing CTX-M beta-lactamases as causes of community acquired infection in France. *Clin Infect Dis.* 2005;40(7):1069-70.
24. Ktari S, Mahjoubi F, Jaoua S, Karray A, Marty N, Ben Redjeb S, Hammami A. Use of molecular subtyping methods to investigate two nosocomial outbreaks due to *Salmonella* Livingstone in Sfax hospital, Tunisia. *Pathol Biol.*2006;54(6):331-6.
25. Mkaouar D, Mahjoubi F, Mezghani S, Znazen A, Ktari S, Hammami A. Resistance to third generation cephalosporins in Sfax hospitals, Tunisia (1999-2005). *Med Mal Infect.*2008;38(6):293-8.
26. Hammami S, Ghozzi R, Burghoffer B, Arlet G, Ben Redjeb S. Mechanisms of carbapenem resistance in non producing metallo-beta-lactamase clinical isolates of *Pseudomonas aeruginosa* from a Tunisian hospital. *Path. Biol.* 2008 (in press).

27. Achour W, Abbassi MS, Cherif A, Jabnoun S, Khrouf N, Ben Hassen A. Nosocomial respiratory infection due to an imipenem-resistant *Pseudomonas aeruginosa* O:12 strain in a Tunis's neonatal intensive care unit. *Pathol Biol.* 2006;54(10):596-9.
28. Lo TS, Welch JM, Alonto AM, Vicaldo-Alonto EA. A review of the carbapenems in clinical use and clinical trials. *Recent Patents Anti-Infect Drug Disc.*2008;3(2):123-31.
29. Saïdani M, Boutiba I, Ghozzi R, Kammoun A, Ben Redjeb S. Bacteriologic profile of bacteremia due to multi-drug resistant bacteria at Charles-Nicolle Hospital of Tunis. *Med Mal Infect.* 2006;36(3):163-6.
30. Boucher HW, Corey GR. Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis.* 2008;46 Suppl 5:S344-9.
31. Park DC, Lee SK, Cha CI, Lee SO, Lee MS, Yeo SG. Antimicrobial resistance of *Staphylococcus* from otorrhea in chronic suppurative otitis media and comparison with results of all isolated Staphylococci. *Eur J Clin Microbiol Infect Dis.* 2008;27(7):571-7.
32. Kim MN, Hwang SH, Pyo YJ, Mun HM, Pai CH. Clonal spread of *Staphylococcus aureus* heterogeneously resistant to vancomycin in a university hospital in Korea. *J Clin Microbiol.* 2002;40(4):1376-80.
33. Nonhoff C, Denis O, Struelens MJ. Low prevalence of methicillin-resistant *Staphylococcus aureus* with reduced susceptibility to glycopeptides in Belgian hospitals. *Clin Microbiol Infect.* 2005;11(3):214-20.
34. Sancak B, Ercis S, Menemenioglu D, Colakoglu S, Haşçelik G. Methicillin-resistant *Staphylococcus aureus* heterogeneously resistant to vancomycin in a Turkish university hospital. *J Antimicrob Chemother.* 2005;56(3):519-23.
35. Sing LH, Koh TH, Wang GC, Hsu LY, Kapi M, Hiramatsu K. Heterogeneous vancomycin-resistant *Staphylococcus aureus* (hetero-VISA) in Singapore. *Int J Antimicrob Agents.* 2005;25(2):177-9.
36. Tenover FC. Vancomycin-resistant *Staphylococcus aureus*: a perfect but geographically limited storm? *Clin Infect Dis.* 2008;46(5):675-7.
37. Jemili-Ben Jomaa M, Boutiba-Ben Boubaker I, Ben Redjeb S. Identification of staphylococcal cassette chromosome mec encoding methicillin resistance in *Staphylococcus aureus* isolates at Charles Nicolle Hospital of Tunis. *Pathol Biol.* 2006;54(8-9):453-5.
38. Ben Ayed S, Boutiba-Ben Boubaker I, Samir E, Ben Redjeb S. Prevalence of agr specificity groups among methicillin resistant *Staphylococcus aureus* circulating at Charles Nicolle hospital of Tunis. *Pathol Biol.* 2006;54(8-9):435-8.
39. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis.* 2008;46 Suppl 5:S378-85.
40. Saidani M, Mesrati I, Benzarti A, Bousetta K, Bousnina S, Hamdoun M, Ben Redjeb S. Pneumonie communautaire à *Staphylococcus aureus* producteur de la toxine de Panton et Valentine: Première description en Tunisie. 2008. *Tun Med* (sous presse).

41. Malik RK, Montecalvo MA, Reale MR, Li K, Maw M, Munoz JL, Gedris C, van Horn K, Carnevale KA, Levi MH, Dweck HS. Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. *Pediatr Infect Dis J.* 1999;18(4):352-6.
42. Olivier CN, Blake RK, Steed LL, Salgado CD. Risk of vancomycin-resistant *Enterococcus* (VRE) bloodstream infection among patients colonized with VRE. *Infect Control Hosp Epidemiol.* 2008;29(5):404-9.
43. Cunha BA. Vancomycin revisited: a reappraisal of clinical use. *Crit Care Clin.* 2008;24(2):393-420.
44. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. *Int J Antimicrob Agents.* 2006;27(6):576.
45. Ergani-Ozcan A, Naas T, Baysan BO, Ogunc D, Inan D, Colak D, Nordmann P. Nosocomial outbreak of vancomycin-resistant *Enterococcus faecium* in a paediatric unit at a Turkish university hospital. *J Antimicrob Chemother.* 2008;61(5):1033-9.
46. Belhaj M, Boutiba-Ben Boubaker I, Ben Redjeb S, Bouchami O. Molecular characterisation of high-level ampicillin-resistant *Enterococcus faecium* isolates from hospitalised patients in Tunis. *Int J Antimicrob Agents.* 2008;32(3):284-6.
47. Ofner-Agostini M, Varia M, Johnston L, Green K, Simor A, Amihod B, Bryce E, Henderson E, Stegenga J, Bergeron F, Canadian Nosocomial Infection Surveillance Program, Gravel D. Infection control and antimicrobial restriction practices for antimicrobial-resistant organisms in Canadian tertiary care hospitals. *Am J Infect Control.* 2007;35(9):563-8.
48. Młynarczyk G, Grzybowska W, Młynarczyk A, Tyski S, Kawecki D, Łuczak M, Durlik M, Paczek L, Chmura A, Rowiński W. Occurrence of glycopeptide-resistant enterococci in transplant medicine internal wards in 2001-2005. *Transplant Proc.* 2007;39(9):2886-9.
49. Hamdad F, Canarelli B, Rousseau F, Thomas D, Biendo M, Eb F, Varon E, Laurans G. *Streptococcus pneumoniae* meningitis in Amiens Hospital between 1990 and 2005. Bacteriological characteristics of strains isolated. *Pathol Biol.* 2007;55(8-9):446-52.
50. Rachdi M, Boutiba-Ben Boubaker I, Moalla S, Smaoui H, Hammami A, Kechrid A, Ben Redjeb S. Phenotypic and genotypic characterization of macrolide resistant *Streptococcus pneumoniae* in Tunisia. *Path Biol.* 2008;56:125-9.
51. Marchese A, Tonoli E, Debbia E, Chito GC. Macrolide resistance mechanisms and expression of phenotypes among *Streptococcus pneumoniae* circulation in Italy. *J Antimicrob Chemother* 1999;44:461-4.

52. Farell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among *Streptococcus pneumoniae* and *Streptococcus pyogenes* isolates from the PROTEKT 1999-2000 study. *J Antimicrob Chemother.*2002;50:39–47.
53. Margaret IP, Lyon DJ, Yong RWW, Chan C, Cheng AFB. Macrolide resistance in *Streptococcus pneumoniae* in Hong Kong. *Antimicrob Agents Chemother* 2000;45:1578–80.
54. Inoue M, Farrell DJ, Kaneko K, Akizawa K, Fujita S, Kaku M, Igari J, Yamaguchi K, Yamanaka K, Murase M, Asari S, Hirakata Y, Baba H, Itaha H. Antimicrobial Susceptibility of Respiratory Tract Pathogens in Japan During PROTEKT Years 1-5 (1999-2004). *Microb Drug Resist.* 2008;14(2):109-17.
55. Srifuengfung S, Tribuddharat C, Champreeda P, Daniels J, Chokephaibulkit K, Wongwan N, Polwichai P. Antimicrobial susceptibility of *Streptococcus pneumoniae* isolated from patients with respiratory tract infections in Thailand. *Southeast Asian J Trop Med Public Health.* 2008;39(3):461-6.
56. Yamanaka N, Hotomi M, Billal DS. Clinical bacteriology and immunology in acute otitis media in children. *J Infect Chemother.*2008;14(3):180-7.
57. Liu Y, Wang H, Chen M, Sun Z, Zhao R, Zhang L, Wang H, Zhang H, Wang L, Chu Y, Liu Y, Ni Y. Serotype distribution and antimicrobial resistance patterns of *Streptococcus pneumoniae* isolated from children in China younger than 5 years. *Diagn Microbiol Infect Dis.* 2008;61(3):256-63.
58. Izumida M, Nagai M, Ohta A, Hashimoto S, Kawado M, Murakami Y, Tada Y, Shigematsu M, Yasui Y, Taniguchi K. Epidemics of drug-resistant bacterial infections observed in infectious disease surveillance in Japan, 2001-2005. *J Epidemiol.*2007;17 Suppl:S42-7.
59. Jacobs MR. Clinical significance of antimicrobial resistance in *Streptococcus pneumoniae*. *S Afr Med J.* 2007;97(11):1133-40.
60. Montagnani F, Fanetti A, Stolzuoli L, Croci L, Arena F, Zanchi A, Cellesi C. Pneumococcal disease in a paediatric population in a hospital of central Italy: a clinical and microbiological case series from 1992 to 2006. *J Infect.* 2008;56(3):179-84.
61. [http://www.santetunisie.rns.tn/msp/actualite/protocoles\\_consensus/RESPIR\\_ATOIRES\\_BASSES.pdf](http://www.santetunisie.rns.tn/msp/actualite/protocoles_consensus/RESPIR_ATOIRES_BASSES.pdf)
62. Chopra I, and Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. *Microbiol. Mol. Biol. Rev.* 2001;65:232–60.
63. Jasir A, Tanna A, Noorani A. et al. ; High rate of tetracycline resistance in *Streptococcus pyogenes* in Iran: an epidemiological study. *J Clin Microbiol.* 2000;38:2103–7.
64. Bingen E, Bidet P, Mihaila-Amrouche L, Doit C, Forcet S, Brahimi N, Bouvet A, Cohen R. Emergence of macrolide-resistant *Streptococcus pyogenes* strains in French children. *Antimicrob Agents Chemother.* 2004;48(9):3559-62.

65. Syrogiannopoulos GA, Grivea IN, Fitoussi F, Doit C, Katopodis GD, Bingen E, Beratis NG. High prevalence of erythromycin resistance of *Streptococcus pyogenes* in Greek children. *Pediatr Infect Dis J.* 2001;20(9):863-8.
66. Hraoui M, Rachdi M, Boutiba-Ben Boubaker I, Ben Redjeb S. Antibiotic susceptibility patterns of group A Streptococcus isolates at Charles Nicolle hospital of Tunis (2000-2005). *Int J Infect Dis.*2006;10(suppl1):S238.
67. [http://www.santetunisie.rns.tn/msp/actualite/protocoles\\_consensus/Angine.pdf](http://www.santetunisie.rns.tn/msp/actualite/protocoles_consensus/Angine.pdf)
68. Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, Yeom JS, Kim CK, Kim SW, Chang HH, Kim YS, Jung SI, Tong Z, Wang Q, Huang SG, Liu JW, Lalitha MK, Tan BH, Van PH, Carlos CC, So T; Asian Network for Surveillance of Resistant Pathogens Study Group. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. *Int J Antimicrob Agents.*2008;31(2):107-14.
69. Gracia M, Díaz C, Coronel P, Gimeno M, García-Rodas R, del Prado G, Huelves L, Ruiz V, Naves PL, Ponte MC, Granizo JJ, Soriano F. Antimicrobial susceptibility of *Haemophilus influenzae* and *Moraxella catarrhalis* isolates in eight Central, East and Baltic European countries in 2005-06: results of the Cefditoren Surveillance Study. *J Antimicrob Chemother.* 2008;61(5):1180-1.
70. Wang A, Yu S, Yao K, Zhang W, Yuan L, Wang Y, Wei J, Shen X, Yang Y. Antimicrobial susceptibility of *Haemophilus influenzae* strains and antibiotics usage patterns in pediatric outpatients: results from a children's hospital in China (2000-2004). *Pediatr Pulmonol.* 2008;43(5):457-62.
71. Sriuengfung S, Chayakulkeeree M, Chokephaibulkit K, Tribuddharat C. Five-year study of antimicrobial susceptibility and beta-lactamase production in *Haemophilus influenzae*. *Southeast Asian J Trop Med Public Health.* 2007;38(4):732-6.